Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Albumin-bound Paclitaxel in Advanced TNBC
NCT05019690Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Fujian Medical University Cancer Hospital. Started Oct 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05019690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019690.